References
- Schaeffer EM, Srinivas S, Antonarakis ES, Armstrong AJ, Cheng HH, D’Amico AV, et al. NCCN Guidelines Version 3.2022. Prostate cancer. 2022 [Internet]. [cited 2022 Jul 02]. Available at: https://www.nccn.org/professionals/physi-cian_gls/pdf/prostate.pdf
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24. doi: 10.1056/ NEJMoa1606220
- Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/ external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33. doi: 10.1016/s0360-3016(03)00784-3
- Deutsche Gesellschaft für Urologie. [Oncology guideline programme (German Cancer Society, German Cancer Aid, AWMF): S3 guideline on prostate carcinoma, long version 6.0, 2021, AWMF registration number: 043/022OL]. [German]. [cited 2021 Jun 16]. Available at: https://www.leitlinienprogramm-onkologie.de/mwg-internal/de5fs23hu73ds/progress?id=6EduY9K1iK09VZIlf8dOvGrff8piCbbjGVH9Qi0SqOo
- Mottet N, van den Bergh RCN, Briers E, van den Broeck T, Cuberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-Update. Part 1: screening, diagnosisi, and local treatment with curative intent. Eur Urol 2021; 79: 243-62. doi: 10.1016/j.eururo.2020.09.042
- Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One 2016; 11: 1-17. doi: 10.1371/journal.pone.0154499
- Wortel RC, Incrocci L, Pos FJ, Van Der Heide UA, Lebesque JV, Aluwini S, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3d-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys 2016; 95: 680-9. doi: 10.1016/j.ijrobp.2016.01.031
- Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol 2011; 6: 1-7. doi: 10.1186/1748-717X-6-145
- Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU. Image-guided radiotherapy for prostate cancer. Transl Androl Urol 2018; 7: 308-20. doi: 10.21037/tau.2017.12.37
- NICE guideline [NG131]. Overview. Prostate cancer: diagnosis and management. Guidance NICE. Nice [Internet]. [cited 2021 Aug 18]. Available at: https://www.nice.org.uk/guidance/ng131
- Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: 125-9. doi: 10.1016/j.ijrobp.2011.11.047
- Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014; 9: 44. doi: 10.1186/1748-717X-9-44
- Zapatero A, Roch M, Büchser D, Castro P, Fernández-Banda L, Pozo G, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol 2017; 19: 1161-7. doi: 10.1007/s12094-017-1655-9
- Singh J, Greer PB, White MA, Parker J, Patterson J, Tang CI, et al. Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys 2013; 85: 1018-23. doi: 10.1016/j.ijrobp.2012.07.2376
- Napieralska A, Majewski W, Kulik R, Głowacki G, Miszczyk L. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Radiat Oncol 2018; 13: 235. doi: 10.1186/s13014-018-1171-2
- NHS general anaestesia. 2021. [Internet]. [cited 2022 Apr 06]. Available at: https://www.nhs.uk/conditions/general-anaesthesia/
- Thieme. General anaesthesia and /or regional anaesthesia in adults and adolescents. Thieme Compliance; 2019.
- Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66: 647-53. doi: 10.1016/j.ijrobp.2006.05.074
- Menzel H G. ICRU Report 83 Prescribing, recording, and reporting photon-beam Intensity-Modulated Radiation Therapy (IMRT). Journal of the ICRU. 2010; 15: 1-2. doi: 10.1093/jicru/ndq001
- Wachter S, Gerstner N, Dorner D, Goldner G, Colotto A, Wambersie A, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 91-100. doi: 10.1016/s0360-3016(01)01821-1
- Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74. doi: 10.1016/j.ijrobp.2006.04.029
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-C
- De Cicco L, Bracelli S. Fiducial markers implantation for prostate image-guided radiotherapy: a report on the transperineal approach. Radiol Medica 2019; 124: 132-5. doi: 10.1007/s11547-018-0949-5
- Valeriani M, Bracci S, Osti MF, Falco T, Agolli L, De Sanctis V, et al. Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy. Radiat Oncol 2013; 8: 1-8. doi: 10.1186/1748-717X-8-137
- Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-6. doi: 10.1200/JCO.2005.05.2530
- Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 2019; 104: 790-7. doi: 10.1016/j.ijrobp.2019.02.045
- Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87. doi: 10.1016/S1470-2045(07)70143-2